Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.

@article{Wolter2010TargetedTI,
  title={Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.},
  author={Pascal Wolter and Patrick Sch{\"o}ffski},
  journal={Acta oncologica},
  year={2010},
  volume={49 1},
  pages={13-23}
}
BACKGROUND AND OBJECTIVES The introduction of targeted therapies has led to improved clinical outcomes in patients with unresectable gastrointestinal stromal tumours (GIST). The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate has been approved as the first-line choice of therapy for this group of patients, while the RTK inhibitor, sunitinib… CONTINUE READING